Piers Ingram, founder and CEO of Singapore-based Hummingbird Bioscience and its U.S. spin-off Callio Therapeutics, is quietly ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...

No patients discontinued gedatolisib due to a treatment-related AE. One (2.3%) patient experienced Grade 3 hyperglycemia. “The 43% ORR reported in patients who received at least three prior lines of ...